Picture this: a groundbreaking approach to battling cancer that empowers your own immune system to obliterate tumors, yet for some, the victory is fleeting as the disease rebounds fiercer than ever. It's a heart-wrenching reality that's pushed scientists to dig deeper. But here's where it gets controversial—could everyday painkillers like aspirin be the secret weapon we never knew we had? Let's explore the exciting yet polarizing findings from recent research that might change how we tackle cancer relapse.
Immunotherapy has transformed the landscape of cancer treatment by harnessing the body's natural defenses to spot and eradicate cancerous growths. For countless individuals, this method proves incredibly successful, causing tumors to dwindle and pushing the disease into a state of remission where it's no longer detectable. However, in certain scenarios, this remission doesn't last, and the cancer returns, often more resilient to further assaults.
A team of investigators at the University of Chicago has uncovered a cunning strategy employed by a select cluster of cancer cells, referred to as tumor-initiating stem cells (tSCs). These elusive cells manipulate neighboring neutrophils—key players in our immune army—transforming them from potential assailants into loyal guardians that shield the tSCs from immunotherapy-fueled immune attacks.
Published in the journal Cancer Cell (link: https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00494-5), this discovery not only sheds light on why some immunotherapies falter but also proposes a promising path forward: pairing immunotherapy with a familiar over-the-counter pain reliever, such as aspirin, to curb cancer's comeback.
'Tumor-initiating stem cells resemble a seed nestled within a fruit, enveloped by a safeguarding layer of neutrophils,' explained Yuxuan Miao, PhD, an Associate Professor in the Ben May Department for Cancer Research at the University of Chicago and the study's lead investigator. 'While immunotherapy dismantles the fruit, the seed remains shielded and can sprout anew. Our work demonstrates how to unveil it.'
Neutrophils serve as the immune system's frontline troops and are frequently the most plentiful immune cells found within tumors. Early in cancer's progression, they often hinder immune responses, aiding tumor expansion. Yet, when immunotherapy kicks in, numerous neutrophils pivot to combat cancer, especially spurred by interferons—powerful chemical messengers that boost anti-cancer efforts. To put it simply, interferons are like alarm signals that rally immune cells to fight.
But here's the part most people miss: not every neutrophil undergoes this transformation. Employing cutting-edge techniques such as single-cell RNA sequencing and spatial transcriptomics, Miao's lab identified a stubborn subset of neutrophils near tSCs that defy immunotherapy. Far from switching to offense, these cells intensify their tumor-supportive behavior, actively barring T cells—another crucial immune fighter—from infiltrating the tumor.
'We were astonished to observe distinct groups of neutrophils coexisting in the tumor's surroundings and reacting so differently to immunotherapy,' noted Weijie Guo, PhD, a Research Scientist in Miao's team (website: https://www.themiaolab.com/) and the paper's first author.
Delving deeper, the scientists revealed that tSCs secrete a fatty substance known as arachidonic acid, which travels to neutrophils and morphs into prostaglandin E2 (PGE2)—a notorious suppressor of immune function. This conversion neutralizes the neutrophils' responsiveness to interferons, those vital signals that typically convert them into tumor destroyers.
'This is a prime illustration of cancer stem cells engineering a personalized protective bubble by reprogramming the immune cells in their vicinity, converting would-be warriors into personal security detail,' Miao remarked.
The conversion of arachidonic acid into PGE2 relies on an enzyme dubbed cyclooxygenase (COX), the very target of medications like aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). Building on this, Miao and colleagues theorized that inhibiting COX could sever the immunosuppressive bond between tSCs and neutrophils.
To test their theory, they conducted experiments on mice afflicted with skin and head and neck squamous cell carcinoma—tumors notorious for harboring stem cells and showing some responsiveness to immunotherapy. Administering aspirin or immunotherapy in isolation failed to fully eradicate the tumors. However, combining the two eradicated the cancers entirely.
And this is the part most people miss: timing plays a pivotal role in these combo treatments. Neutrophils continuously rotate in and out of the tumor zone, so administering the COX inhibitor beforehand preps incoming neutrophils to heed interferon signals, preventing them from being pre-conditioned by PGE2.
'Neutrophils aren't simply toggling from foe to friend; the PGE2 messaging must be silenced when interferon cues arrive,' Miao elaborated. 'That's the reason treatment order and timing are so essential.'
Much like how healthy stem cells in tissues maintain balance by curbing inflammation, cancer stem cells exploit similar tactics to evade annihilation. This research contributes to an expanding collection of studies illustrating how tumor stem cells misuse the body's self-protective mechanisms to foster recurrence.
'We see immune modulation as a fundamental trait in stem cells, but in cancerous settings, it's exploited to encourage comeback,' Miao stated.
These insights pave the way for innovative blended therapies that could amplify existing immunotherapies, potentially lengthening remissions or averting relapse in cancers propelled by tumor stem cells.
'Since these are already FDA-approved medications, strategically deploying them could elevate immunotherapy's impact and duration,' Miao added.
Upcoming investigations will aim to pinpoint more ways to disrupt the ties between cancer-initiating stem cells and neutrophils, aiming for superior treatments. The group also plans to investigate if these dynamics play out in other stubborn tumor types, particularly those resistant to standard care.
The study, titled 'Tumor-Initiating Stem Cells Fine-tune the Plasticity of Neutrophils to Sculpt a Protective Niche' (link: https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00494-5), received backing from University of Chicago start-up funds, the Cancer Research Foundation Breakthrough Board, Cancer Center Support Grant, pilot grants from the University of Chicago Medicine Comprehensive Cancer Center, and awards from the National Institutes of Health (NIH), American Cancer Society, V Foundation, American Association for Cancer Research, and the Cancer Research Foundation.
Collaborating authors encompass Jingyun Luan, Xuejie Huang, Daniel Leon, Sophie Gang, Benjamin Nicholson, Breanna Bertacchi, Diana Bolotin, Mark Lingen, Evgeny Izumchenko, Ari Rosenberg, Nishant Agrawal, Everett Vokes, and Alexander Pearson from the University of Chicago; Shuh Narumiya from Kyoto University's Graduate School of Medicine in Japan; Siwakorn Punyawatthananukool from Kyoto University's Graduate School of Medicine in Japan and Mahidol University in Bangkok; Matthias Gunzer from the University of Duisburg-Essen in Germany and Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V. in Dortmund, Germany; Iván Ballesteros from Centro Nacional de Investigaciones Cardiovasculares Carlos III and Universidad Carlos III de Madrid in Spain; and Andrés Hidalgo from Yale University School of Medicine in New Haven, Connecticut, USA.
Now, let's stir the pot a bit. While aspirin is hailed as a cheap, accessible ally, some might argue it's risky in cancer patients—who often have unique health profiles that could complicate things. Is repurposing everyday drugs like this a stroke of genius, or could it lead to unintended side effects we haven't foreseen? Does the promise of preventing relapse outweigh potential downsides? We'd love to hear your take—do you see this as a game-changer, or are you skeptical about jumping from pain relief to cancer combat? Drop your thoughts in the comments below and let's discuss!
